Five-year outcomes of retinal vein occlusion provide long term data for anti-VEGF treatments on real-world data

Researchers at the Sydney Institute of Vision Science, in New South Wales, Australia report that good long-term efficacy of anti-VEGF therapy over 5 years provides a real-world setting, albeit different to the outcome data reported from clinical trial publications. In follow-up to real-world 5-year outcome data on a retrospective population, the results indicate that a mean change in visual acuity (VA) was +9.6 ± 21.6 letters among CRVO (central retinal vein occlusions) eyes and +14.2 ± 15.6 letters among eyes with BRVO (branch retinal vein occlusions)(p=0.001). The proportion of eyes with a three-line improvement of vision (15 letters) at 5 years was 22 % and this compares to clinical trial data reported in the literature.

 

As established, RVO (retinal vein occlusions) is generally classified into two primary categories depending on the location of obstruction: CRVO involving the entire central retinal vein, while BRVO is when only one branch of the central vein is affected. Alternatively, hemi-RVO (HRVO) may be either as a subtype of CRVO involving with the anterior part of the central retinal vein or a BRVO as the first branch of the central retinal vein. Anti-VEGF studies to treat RVO have provided several clinical trial data, usually reporting an over 12-month duration including COPERNICUS, GALILEO, BRAVO, CRUISE and VIBRANT.  These studies generally use intravitreal (IVT) injections of VEGF inhibitors such as bevacizumab, ranibizumab and aflibercept however, there is limited data available over long term outcomes in a real-world setting. As commented from the Australian research study, “patients in clinical trials tend to be healthier and younger and need to be able to commit to the rigorous schedule of the clinical trial”.  Consequently, it is important to assess how treatments for anti-VEGF outcomes can compare against longer duration for treatment (>5 years) and potentially compared in a heterogenous population.

 

Idealised patients recruited into clinical trials have found >15 letter ETDRS treatment improvements after 1 year range between 53% to 60% (VIBRANT: 52.7%; COPERNICUS: 56% and GALILEO: 60%). Alternatively, real-world data for 5 years on outcomes across a retrospective cohort show a 22% gain of ≥15 ETDRS letters.  It is not unusual to see clinical trial data gains among heathier patients, especially when a rigorous controlled study and other inclusion and exclusion criteria could also show higher gains.  Notwithstanding, the current 5-year analysis provides the significant benefit to help us understand how anti-VEGF medications can operate in real-world conditions.  Broader studies may additionally demonstrate further activities across other jurisdictions for larger numbers and up to 10 year outcomes.

12 thoughts on “Five-year outcomes of retinal vein occlusion provide long term data for anti-VEGF treatments on real-world data”

  1. Thanks for a marvelous posting! I actually enjoyed reading it,
    you could be a great author.I will make certain to bookmark
    your blog and may come back someday. I want to encourage you continue your
    great job, have a nice weekend!

  2. I do not know whether it’s just me or if everyone else experiencing issues with your
    website. It appears as though some of the written text
    on your content are running off the screen. Can somebody else please comment and let me know if
    this is happening to them as well? This could be a issue
    with my internet browser because I’ve had this happen previously.
    Cheers

  3. I just want to say I am just very new to weblog and definitely loved this web page. Almost certainly I’m want to bookmark your website . You absolutely come with wonderful articles. Kudos for sharing with us your website page.

  4. Simply a smiling visitor here to share the love (:, btw outstanding design . “Audacity, more audacity and always audacity.” by Georges Jacques Danton.

  5. An excellent share, I just provided this onto a colleague who was doing a little evaluation on this. As well as he actually got me breakfast since I located it for him. smile. So let me reword that: Thnx for the reward! Yet yeah Thnkx for spending the time to discuss this, I feel strongly about it and enjoy reading more on this topic. Ideally, as you become expertise, would certainly you mind upgrading your blog with more details? It is very useful for me. Huge thumb up for this blog post!

  6. I simply wished to thank you very much yet again. I’m not certain the things I could possibly have accomplished in the absence of those smart ideas shared by you directly on that subject matter. Previously it was a very troublesome circumstance for me personally, nevertheless discovering this expert mode you handled it took me to cry over delight. Now i’m thankful for your information and as well , expect you know what an amazing job you happen to be providing teaching the mediocre ones using a blog. Probably you have never encountered all of us.

Leave a Reply

Your email address will not be published.